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Iron therapy and cardiovascular disease. Intensive iron therapy The “iron hypothesis” has broad explanatory power
is now a generally accepted adjunct for the treatment of renal [1–4]. Decreased levels of stored iron may be involved
anemia with recombinant human erythropoietin. However, not only in the protection against myocardial infarctionwith the emerging role of iron in cardiovascular disease, carci-
enjoyed by menstruating women, but also in the lownogenesis, infectious diseases, and other disorders, it is no
heart disease rates seen among impoverished people inlonger appropriate to assume that any amount of stored iron
is safe until proven otherwise. In this article, the history and the world’s poorer countries. In these populations, the
current status of the “iron hypothesis” on ischemic heart dis- age-dependent rise in stored iron is blunted by high-fiber
ease are briefly reviewed, followed by comments on iron man- diets that retard absorption of iron and by prevalentagement practices for renal patients.
parasites that cause chronic blood loss from gut and
bladder. Increased iron stores may have had a major role
in the emergence of the present epidemic of myocardialThe hypothesis that iron depletion protects against
infarction in developed nations early in this century.ischemic heart disease was proposed in 1981 as an expla-
Improvements in public sanitation protected the popula-nation for the striking sex difference in heart disease
tion from iron-wasting gastrointestinal parasites, and in-rates [1–4]. The virtual absence of myocardial infarction
creased consumption of meat assured a source of easilyin menstruating women is associated with quite low levels
absorbable iron. Iron loss may be part of the explanationof stored iron. Typically little or no excess iron is accumu-
for lower disease rates associated with long-term regularlated as long as regular monthly bleeding continues.
aspirin use. Gastrointestinal microbleeding from dailyMenstruating women continue to maintain the negligible
use of aspirin can cause a cumulative loss of iron equallevels of stored iron found in both men and women
to that of typical menstrual iron losses.before age 20. Whole blood contains approximately 0.5
The most important mechanisms by which iron deple-mg of iron per milliliter. Typical menstrual blood loss
tion protects have not been defined, and unexpectedamounts to 30 to 60 ml per month, representing a loss
modes of protection cannot be confidently ruled out. Itof 180 to 360 mg of iron per year. When menstrual iron
is likely that iron depletion protects by more than oneloss ceases for any reason, there is a prompt increase in
mechanism. The two leading candidates appear to bethe heart disease rate.
(1) a decrease in atherogenesis and (2) a decrease inMen lack the menstrual iron leak and undergo a pro-
myocardial injury following ischemic events.gressive accumulation rising rapidly with age from the
It has been shown in experimental studies that ironlow levels of adolescence. On the order of 1000 mg of
overload enhances [5] and iron depletion decreases for-sequestered iron is amassed by middle age. At age 45,
mation of atherosclerotic plaque [6]. Deliberate ironmen have roughly four times more iron in storage than
depletion in men increases the resistance of low-densitywomen. An increasing incidence of myocardial infarction
lipoprotein to oxidation [7] and is associated with anparallels the acquisition of stored iron starting two de-
increase in serum concentrations of high-density lipopro-cades earlier in men than in women. The close parallels
tein [8]. A recent study suggests that serum ferritin valuesbetween rising heart disease rates and rising levels of
stored iron at a young age in men and in later years in over 50 ng/ml are associated with a marked increase in
women prompted the suggestion that stored iron may carotid atherosclerosis in men and in women [9].
have a central role in heart disease [1–4]. As women close A preponderance of evidence suggests that deferoxa-
the large stored iron gap with men, they progressively mine can protect heart muscle from reperfusion injury
close the equally large difference in heart disease rates. [2]. Hearts in these studies were taken from subjects who
were not iron overloaded in any conventional sense. The
data collectively support the possibility that only a veryKey words: erythropoietin, ischemic heart disease, myocardial in-
farction, anemia. small burden of stored iron is required to promote heart
muscle injury after an ischemic event. A given occlusive 1999 by the International Society of Nephrology
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event may or may not result in a clinically apparent in- range is benign. It is clear that symptomatic hemochro-
matosis can be associated with serum ferritin values farfarction, depending on the burden of stored iron present.
Epidemiologic studies to date have not produced con- below 1000 ng/ml at presentation. There are also experi-
mental data that show increasing resistance to forms ofsensus on the role of iron in cardiovascular disease. De-
bate on the merits of the hypothesis has been muddied oxygen-radical–mediated injury in iron-depleted sub-
jects [16–20].by several flawed negative studies [4]. A common flaw
is that stored iron has been measured by inappropriate Iron overload should be defined as a clinical situation
in which iron not needed or being used for erythropoie-methods. A number of studies have used experimental
designs that reflect an apparent misunderstanding of the sis, that is, stored iron, contributes to a pathologic pro-
cess. Iron overload cannot be excluded on the basis ofiron hypothesis. In a 1994 editorial, Ascherio and Willett
nonetheless acknowledged that the iron hypothesis can- measurements of iron in storage. It is not possible to
assign a minimum cut-off value for stored iron or serumnot be rejected on the basis of available data: “Stronger
evidence is needed before the hypothesis is rejected that ferritin in the definition of iron overload. As noted earlier
here, very small amounts of such iron may significantlygreater iron stores increase the incidence of coronary heart
disease or death from myocardial infarction” [10]. In promote myocardial injury after an ischemic event. In
postischemic hearts, the stored iron burden, althoughother words, despite more than a decade of investigation
and adversarial discussion, the hypothesis has not been small by conventional standards, is excessive in that it
contributes to tissue pathology. Another example con-invalidated. More recent studies confirm a major predic-
tion of the hypothesis that volunteer blood donation is cerns chronic hepatitis C. Recent work suggests that
removal of “normal” amounts of storage iron can oftenassociated with a large and significant decrease in athero-
sclerosis and vascular events [9, 11, 12]. decrease the serum aminotransferase concentrations.
Continued removal of iron from a patient with appar-
ently total iron depletion can achieve additional decre-
IRON THERAPY IN RENAL PATIENTS
ments in aminotransferase levels [21]. In this situation,
In formulating strategies for avoiding anemia in renal it has been suggested that aminotransferase levels be
patients, it appears to this observer that too little atten- used instead of serum ferritin to assure that all of the
tion has been given to outcome, and too much has been overloading iron is removed. Chronic hepatitis is thus
devoted to achieving arbitrary hemoglobin targets. Po- an example of iron overload from conventionally trivial
tential hazards of stored iron have been largely ignored. amounts of storage iron.
These hazards may not be apparent in the short run. The available data are not adequate to define precisely
Failure to demonstrate cardiovascular toxicity in short- the relationship between net harm and level of iron over-
term studies with limited numbers of subjects does not load. Neither the shape of the curve nor the x intercept
assure that there is no myocardial injury [13]. “Free” is known with certainty. In other words, at what level of
plasma iron may cause myocardial injury. In the state stored iron does net harm approach zero? The data do
of transferrin oversaturation, it must not be assumed not rule out the possibility that stored iron may need to
that other ligands prevent the appearance of such free be reduced to zero to minimize harm. Clinical circum-
iron. There is a specific assay for free iron in plasma [14] stances may alter the potential for harm from a given
that should be used to determine the concentration of burden of stored iron. For example, a shift toward acid
free iron during intravenous iron therapy. It is likely that pH can release iron from transferrin, and a flux of super-
free iron regularly occurs in plasma during and following oxide ion, for example, from activated neutrophils, can
intravenous iron therapy. Cumulative damage to heart free iron from its ferritin storage sites. The most conser-
and other tissues cannot be ruled out on the basis of vative approach would be to place the burden of proof
available evidence. with those who maintain that any stored iron is safe.
Chronic deleterious effects of stored iron overload are The concept of functional iron deficiency needs to be
a concern beyond the issue of acute increases in free systematically re-examined. Studies are needed of alterna-
plasma iron. A key question concerns the definition of tive ways of mobilizing endogenous iron stores during
iron overload. Some have suggested that the serum ferri- erythropoietin treatment. Perhaps simultaneous use of
tin must exceed 1000 ng/ml before iron overload occurs erythropoietin and deferoxamine would increase the mo-
[15]. In my view, this is far too high. With this inadequate bilization of iron from its sequestered sites. The rate of
data base, medical judgement must play a dominant role stored iron removal by phlebotomy in hemochromatosis
in the formulation of guidelines. The case for using a patients is highly variable. Stored iron in some sites is
ferritin value of 1000 ng/ml to define the threshold of iron more resistant to mobilization and requires prolonged
overload is based on the lack of a consensus on specific phlebotomy treatment and much patience on the part
hazards of serum ferritin at this level. However, there is of physician and patient for complete removal. In pa-
tients with apparently unavailable stored iron, more pro-also no convincing evidence that serum ferritin in this
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